Table 2
Comparison of 86 patients before treatment and 24 weeks later
| Group | Before | After | Significance* |
|---|---|---|---|
| Unless otherwise stated, values are mean (SD). *p value of paired t test. aPatients or carers worse at 24 weeks, after treatment, on these measures. HAD, hospital anxiety and depression scale; PD, Parkinson’s disease; PDQ-39, Parkinson’s disease questionnaire; SF-36, short form 36; UPDRS, unified Parkinson’s disease rating scale; VAS, visual analogue scale. | |||
| Patients (n=86) | |||
| Male:female (n) | 50:36 | 50:36 | |
| Age (years) | 71.3 (8.6) | ||
| PD disability questionnaire | 51.7 (17.6) | 54.8 (18.9) | 0.031a |
| PDQ-39 | 25.5 (10.7) | 26.0 (12.7) | 0.687 |
| SF-36 physical component summary | 29.5 (11.1) | 27.28 (10.9) | 0.046a |
| SF-36 mental component summary | 51.0 (8.4) | 50.5 (10.3) | 0.655 |
| SF-36 mental health subscale | 71.5 (13.5) | 70.3 (17.2) | 0.474 |
| SF-36 general health subscale | 50.3 (21.0) | 38.65 (19.5) | <0.001a |
| Euroqol scale | 0.72 (0.22) | 0.66 (0.21) | 0.026a |
| Euroqol VAS | 71.9 (16.4) | 68.2 (19.4) | 0.110 |
| Stand-walk-sit test (s) | 22.9 (18.2), n=82 | 22.2 (13.5), n=83 | 0.752 |
| Nine hole peg test seconds | 22.4 (24.8), n=83 | 20.7 (13.0), n=83 | 0.313 |
| UPRS, speech | 1.42 (0.96) | 1.51 (0.95) | 0.380 |
| UPRS, salivation | 1.27 (1.22) | 1.36 (1.10) | 0.369 |
| UPRS, swallowing | 0.91 (1.05) | 0.97 (1.05) | 0.607 |
| UPRS, writing | 2.29 (1.16) | 2.38 (1.12) | 0.729 |
| HAD, anxiety | 6.0 (3.4) | 5.8 (3.21) | 0.729 |
| HAD, depression | 5.2 (3.6) | 5.0 (3.2) | 0.638 |
| Carers (n=63) | |||
| Carer strain index | 3.1 (2.7), n=61 | 3.8 (3.2), n=62 | 0.045a |
| Euroqol scale | 0.82 (0.22) | 0.79 (0.24) | 0.235 |
| Euroqol VAS | 78.0 (16.6) | 77.5 (19.5) | 0.873 |
